Gender differences in multiple sclerosis: Induction of estrogen signaling in male and progesterone signaling in female lesions

Journal of Neuropathology and Experimental Neurology

Volumn 73, Issue 2, 2014, Pages 123-135

  Luchetti, Sabina ^a   Van Eden, Corbert G ^a   Schuurman, Karianne ^a   Van Strien, Miriam E ^b   Swaab, Dick F ^a,c   Huitinga, Inge ^a  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b Astrocyte Biology and Neurodegeneration   (Netherlands)

^c Neuropsychiatric Disorders ^*  (Netherlands)

Author keywords

Gene expression; Multiple sclerosis; Neurosteroids; Postmortem human brain; Sex differences

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AROMATASE; ESTROGEN; ESTROGEN RECEPTOR BETA; MESSENGER RNA; PROGESTERONE; PROGESTERONE RECEPTOR; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; ASTROCYTE CULTURE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INDUCTION; ESTROGEN SYNTHESIS; FEMALE; GENE EXPRESSION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIAL CELL CULTURE; MIDDLE AGED; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGESTERONE SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SIGNAL TRANSDUCTION; STEROIDOGENESIS; WHITE MATTER LESION;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE; BRAIN; CYTOKINES; ESTROGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED; POSTMORTEM CHANGES; PROGESTERONE; RECEPTORS, ESTROGEN; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION;

EID: 84892716729     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0000000000000037     Document Type: Article

References (52)

1. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: A systematic review. Neurology 2008;71:129-35
2. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 2003;126:770-82
3. Weinshenker BG, Rice GP, Noseworthy JH, et al. The natural history of multiple sclerosis: A geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991;114: 1057-67
4. Pozzilli C, Tomassini V, Marinelli F, et al. "Gender gap" in multiple sclerosis: Magnetic resonance imaging evidence. Eur J Neurol 2003;10: 95-97
5. Koning N, Bö L, Hoek RM, et al. Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions. Ann Neurol 2007;62: 504-14
6. Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res 2009;175:239-51
7. Schwendimann RN, Alekseeva N. Gender issues in multiple sclerosis. Int Rev Neurobiol 2007;79:377-92
8. Robel P, Baulieu EE. Neurosteroids: Biosynthesis and function. Crit Rev Neurobiol 1995;9:383-94
9. El-Etr M, Ghoumari A, Sitruk-Ware R, et al. Hormonal influences in multiple sclerosis: New therapeutic benefits for steroids. Maturitas 2011; 68:47-51
10. Kipp M, Amor S, Krauth R, et al. Multiple sclerosis: Neuroprotective alliance of estrogen-progesterone and gender. Front Neuroendocrinol 2012;33:1-16
11. Spence RD, Voskuhl RR. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front Neuroendocrinol 2012;33:105-15
12. Garcia-Segura LM, Sanz A, Mendez P. Cross-talk between IGF-I and estradiol in the brain: Focus on neuroprotection. Neuroendocrinology 2006;84:275-79
13. He J, Evans CO, Hoffman SW, et al. Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp Neurol 2004;189:404-12
14. Morita K, Her S. Progesterone pretreatment enhances serotonin-stimulated BDNF gene expression in rat c6 glioma cells through production of 5alpha-reduced neurosteroids. J Mol Neurosci 2008;34:193-200
15. Vegeto E, Belcredito S, Etteri S, et al. Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci USA 2003;100:9614-19
16. Gago N, El-EtrM, Sananes N, et al. 3Alpha, 5alpha-tetrahydroprogesterone (allopregnanolone) and gamma-aminobutyric acid: Autocrine/paracrine interactions in the control of neonatal PSA-NCAM+ progenitor proliferation. J Neurosci Res 2004;78:770-83
17. Noorbakhsh F, Ellestad KK, Maingat F, et al. Impaired neurosteroid synthesis in multiple sclerosis. Brain 2011;134:2703-21
18. van der Valk P, De Groot CJ. Staging of multiple sclerosis (MS) lesions: Pathology of the time frame of MS. Neuropathol Appl Neurobiol 2000; 26:2-10
19. Luchetti S, Bossers K, Frajese GV, et al. Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease. Brain Pathol 2010;20:945-51
20. Vandesompele J, De PK, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034
21. Thigpen AE, Silver RI, Guileyardo JM, et al. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993;92:903-10
22. Burczynski ME, Harvey RG, Penning TM. Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: Oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry 1998;37:6781-90
23. Smithgall TE, Penning TM. Electrophoretic and immunochemical characterization of 3 alpha-hydroxysteroid/dihydrodiol dehydrogenases of rat tissues. Biochem J 1988;254:715-21
24. Ishunina TA, van BD, van der Meulen G, et al. Diminished aromatase immunoreactivity in the hypothalamus, but not in the basal forebrain nuclei in Alzheimer's disease. Neurobiol Aging 2005;26:173-94
25. Thomas JL, Mason JI, Brandt S, et al. Differences in substrate and inhibitor kinetics of human type 1 and type 2 3beta-hydroxysteroid dehydrogenase are explained by the type 1 mutant, H156Y. Endocr Res 2002; 28:471-75
26. Bao AM, Fischer DF, Wu YH, et al. A direct androgenic involvement in the expression of human corticotropin-releasing hormone. Mol Psychiatry 2006;11:567-76
27. Melief J, Koning N, Schuurman KG, et al. Phenotyping primary human microglia: Tight regulation of LPS responsiveness. Glia 2012;60:1506-17
28. Smolders J, Schuurman KG, van Strien ME, et al. Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosisYaffected brain tissue. J Neuropathol Exp Neurol 2013;72:91-105
29. Dufort I, Rheault P, Huang XF, et al. Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 1999;140:568-74
30. Penning TM, Burczynski ME, Jez JM, et al. Human 3alphahydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: Functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000;351:67-77
31. Messingham KA, Heinrich SA, Kovacs EJ. Estrogen restores cellular immunity in injured male mice via suppression of interleukin-6 production. J Leukoc Biol 2001;70:887-95
32. Giraud SN, Caron CM, Pham-Dinh D, et al. Estradiol inhibits ongoing autoimmune neuroinflammation and NFkappaB-dependent CCL2 expression in reactive astrocytes. Proc Natl Acad Sci USA 2010;107:8416-21
33. Subramanian S, Matejuk A, Zamora A, et al. Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system. J Immunol 2003;170:1548-55
34. Bebo BF Jr, Fyfe-Johnson A, Adlard K, et al. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol 2001;166:2080-89
35. Liu HB, Loo KK, Palaszynski K, et al. Estrogen receptor alpha mediates estrogen's immune protection in autoimmune disease. J Immunol 2003; 171:6936-40
36. Tiwari-Woodruff S, Morales LB, Lee R, et al. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proc Natl Acad Sci USA 2007;104: 14813-18
37. Wisdom AJ, Cao Y, Itoh N, et al. Estrogen receptor-beta ligand treatment after disease onset is neuroprotective in the multiple sclerosis model. J Neurosci Res 2013;91:901-8
38. Saijo K, Collier JG, Li AC, et al. An ADIOL-ERbeta-CtBP transrepression pathway negatively regulates microglia-mediated inflammation. Cell 2011;145:584-95
39. Caruso D, D'Intino G, Giatti S, et al. Sex-dimorphic changes in neuroactive steroid levels after chronic experimental autoimmune encephalomyelitis. J Neurochem 2010;114:921-32
40. Giatti S, Caruso D, Boraso M, et al. Neuroprotective effects of progesterone in chronic experimental autoimmune encephalomyelitis. J Neuroendocrinol 2012;24:851-61
41. Ghoumari AM, Ibanez C, El-Etr M, et al. Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J Neurochem 2003;86:848-59
42. Ghoumari AM, Baulieu EE, Schumacher M. Progesterone increases oligodendroglial cell proliferation in rat cerebellar slice cultures. Neuroscience 2005;135:47-58
43. Muller E, Kerschbaum HH. Progesterone and its metabolites 5-dihydroprogesterone and 5-3-tetrahydroprogesterone decrease LPS-induced NO release in the murine microglial cell line, BV-2. Neuro Endocrinol Lett 2006;27:675-78
44. Palaszynski KM, Loo KK, Ashouri JF, et al. Androgens are protective in experimental autoimmune encephalomyelitis: Implications for multiple sclerosis. J Neuroimmunol 2004;146:144-52
45. Hussain R, Ghoumari AM, Bielecki B, et al. The neural androgen receptor: A therapeutic target for myelin repair in chronic demyelination. Brain 2013;136:132-46
46. Santos-Galindo M, Acaz-Fonseca E, Bellini MJ, et al. Sex differences in the inflammatory response of primary astrocytes to lipopolysaccharide. Biol Sex Differ 2011;2:7
47. Garcia-Ovejero D, Azcoitia I, Doncarlos LL, et al. Glia-neuron crosstalk in the neuroprotective mechanisms of sex steroid hormones. Brain Res Brain Res Rev 2005;48:273-86
48. Pawlak J, Brito V, Kuppers E, et al. Regulation of glutamate transporter GLAST and GLT-1 expression in astrocytes by estrogen. Brain Res Mol Brain Res 2005;138:1-7
49. Kipp M, Karakaya S, Johann S, et al. Oestrogen and progesterone reduce lipopolysaccharide-induced expression of tumour necrosis factor-alpha and interleukin-18 in midbrain astrocytes. J Neuroendocrinol 2007;19: 819-22
50. Spence RD, Hamby ME, Umeda E, et al. Neuroprotection mediated through estrogen receptorYalpha in astrocytes. Proc Natl Acad Sci USA 2011;108:8867-72
51. Drew PD, Chavis JA. Female sex steroids: Effects upon microglial cell activation. J Neuroimmunol 2000;111:77-85
52. Ganter S, Northoff H, Mannel D, et al. Growth control of cultured microglia. J Neurosci Res 1992;33:218-30